Even as markets took a pause, there's still plenty of action in individual stock names.
News & Analysis: Illumina
The genomic sequencing pioneer reported great fourth-quarter results.
ILMN earnings call for the period ending January 3, 2021.
The genomics leader got a boost from identifying new COVID variants, and won a patent lawsuit.
Analysts' pessimism about these stocks appears to be off-base.
No matter the outcome of the upcoming election, these industry leaders are set to excel in 2021 and beyond.
The genomic-sequencing leader is recovering more quickly from the COVID-19 pandemic than it anticipated.
ILMN earnings call for the period ending September 27, 2020.
These two stocks have very different methods of generating returns.
How COVID-19 is treated in the future could be altered by recent breakthrough research.